South Korea is making a coordinated government push to help its pharma biotech startups reach global scale. The Ministry of SMEs and Startups and the Ministry of Health and Welfare held a joint policy forum at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seoul, where they announced the “Full-Cycle Collaboration Plan for Pharma Biotech Venture Development” — a cross-ministry framework designed to support ventures from founding all the way through to global market entry.

The plan is a direct follow-up to the national startup strategy session the President chaired in January, and is the first concrete cross-ministry action tied to the Ministry of SMEs and Startups’ broader “Startup for All” initiative to focus squarely on pharma biotech.

The rationale is hard to argue with. The global pharmaceutical market is roughly three times the size of the semiconductor industry ($540 billion) and twelve times that of shipbuilding ($140 billion), and it’s expected to grow at a compound annual rate of over 4.7% through 2028. Korea’s own biopharma sector has been racking up wins: Celltrion’s Remsima now generates over $800 million (KRW 1.2 trillion) in annual sales, and Yuhan Corporation and Oscotec’s Lazertinib won U.S. FDA approval in August 2024. Between 2018 and 2023, Korea completed 43 biotech IPOs — 4.8 times Japan’s nine over the same period — and technology licensing deals hit a record high in 2025, with 22 transactions totaling approximately $14.1 billion (KRW 21.1 trillion). Korea’s pharma pipeline now stands at 3,233 compounds, placing it third worldwide behind the U.S. and China.

The problem, as the government sees it, is that promising companies keep running out of runway. Funding tends to dry up right as ventures prepare to enter clinical trials, and partnerships or commercialization support often come too late to matter. The new plan tries to close that gap by pairing the Ministry of SMEs and Startups’ commercialization and R&D funding machinery with the Ministry of Health and Welfare’s depth in clinical-stage open innovation, hospital network access, and overseas market entry support.

The “4UP Strategy”

Both ministries will jointly identify pharma biotech companies with blockbuster potential — defined as those with realistic prospects of reaching $667 million (KRW 1 trillion) or more in annual revenue — and channel them into a dedicated, high-intensity support track.

Scale-Up through Innovation Funding. Ventures selected through the Scale-Up TIPS platform will receive R&D grants of $1.3–2 million (KRW 2–3 billion), bundled automatically — without additional review — with the Ministry of Health and Welfare’s K-BioHealth Global Expansion Package, biohealth infrastructure access, and export vouchers. A relay-style funding structure will link technology guarantees and the national new drug development program to keep capital flowing from early discovery all the way into clinical trials. The two ministries will also deepen connections between their policy funds to build a more cohesive investment chain from candidate identification through commercialization.

Speed-Up through Open Innovation. A new “Global Open Innovation Activation Program,” backed by approximately $6.9 million (KRW 10.4 billion), will walk pharma ventures through every stage of big pharma engagement — from initial exploratory discussions to signed technology transfer agreements. Support includes access to international innovation hubs such as the Boston CIC and Shonan iPark in Japan. Back home, the government will launch new joint R&D tracks pairing AI startups with pharma companies, improve access to medical data, and revise the certification criteria for innovative pharma firms.

Level-Up through Ecosystem Building. Shared access to research equipment and data will be broadened, and a virtual platform will be stood up to better connect regional biotech clusters. Both ministries will work directly with industry to surface and fix regulatory friction points, while building a dedicated statistics and monitoring framework for the pharma biotech sector — one that ties companies, research institutions, hospitals, and investors into a more functional ecosystem.

Synergy-Up through Field-Driven Policy. For ventures still in the earliest stages, both ministries will jointly design new programs to fill the gaps that existing policy hasn’t addressed. The centerpiece is a new “AI-Assisted Pharma Biotech–Pharma Company Joint R&D” program to encourage earlier-stage collaboration, alongside an integrated support track called “K-Bio Tech Commercialization Co-Sprint” that handles everything from R&D strategy through infrastructure access to global launch.

“Pharma biotech ventures often have the technology, but the investment, partnerships, and commercialization support just don’t show up at the right time,” said Minister Seongsuk Han of the Ministry of SMEs and Startups. “This plan is about connecting those pieces so companies can scale faster and open innovation can actually move the needle on commercialization.”

Minister Eunkyung Jeong of the Ministry of Health and Welfare framed the stakes in broader terms: “Pharma biotech ventures are central to Korea’s ambition to lead globally. By working across ministries, we want to build a growth ladder — from R&D through to global expansion — where innovation drives industrial growth, and that growth ultimately comes back around as better health outcomes for people.”

The government expects the plan to generate more global licensing deals and faster clinical trial entries, building out what it calls the “K-Bio Growth Ladder” — a connected pipeline from early investment through to international commercialization.